Is Telehealth Semaglutide or Tirzepatide Legal? What the Law Actually Says

Headlines about counterfeit online pharmacies and gray-market peptide sellers have made one question extremely common: is it actually legal to get semaglutide or tirzepatide through telehealth? The short answer is yes, when the process runs through a licensed physician and a licensed pharmacy. The longer answer, and the part that actually protects you, is understanding exactly what makes a program legitimate versus a program that only looks legitimate.

*This article is for informational purposes only. It is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.*

*Compounded semaglutide and tirzepatide are not FDA-approved. They are not equivalent to, or interchangeable with, FDA-approved brand-name products. Prescriva LLC (DBA Prescriva) is a management services organization and does not practice medicine. All clinical decisions are made by independently licensed healthcare providers.*

---

The Short Answer

Getting semaglutide or tirzepatide through telehealth is legal when two things are true at the same time: a physician licensed in your state evaluates you and writes a valid, patient-specific prescription, and that prescription is filled by a pharmacy operating within its legal scope, whether that is a retail pharmacy dispensing an FDA-approved brand like Wegovy or Zepbound, or a state-licensed 503A compounding pharmacy preparing a compounded version for a documented clinical reason.

What is not legal, and what generates most of the news coverage that makes people nervous, is everything that skips those steps: no real clinical evaluation, no individual prescription, unlicensed sellers shipping directly to consumers, and products sourced from unregulated ingredient suppliers rather than FDA-registered manufacturers. Understanding the difference is the whole point of this guide.

---

How Telehealth Prescribing Actually Works, Legally

Telehealth prescribing itself is legal in all 50 states, and it has been for years. The legal framework rests on a few consistent requirements:

The provider must be licensed in the state where you live. This is the one rule that never has an exception. A physician licensed only in California cannot legally prescribe to a patient physically located in Ohio. Legitimate telehealth platforms verify state licensure for every patient before a provider is matched to them.

A real clinical evaluation has to happen. Depending on the state, this can be a live video visit or, in many states, a thorough asynchronous intake (detailed health history, current medications, relevant labs) reviewed directly by the prescribing provider. What is not legally defensible, and what has led to real disciplinary action, is a provider issuing a prescription based on a short questionnaire with no meaningful clinical review behind it. A Mississippi physician had a license suspended for exactly this reason: prescribing based on instant-messaging exchanges without an adequate clinical evaluation.

Informed consent is required everywhere. You should be told what the medication is, what it is not, what the risks are, and what alternatives exist, in writing, before treatment begins.

One detail that matters here: semaglutide and tirzepatide are not controlled substances. That means the stricter DEA telehealth rules that apply to controlled-substance prescribing (used for medications with abuse potential) simply do not apply to GLP-1 medications. This is one of the reasons telehealth access to this drug class has expanded so quickly and legally over the past few years.

*Legitimate telehealth prescribing always starts with a licensed physician reviewing your specific medical history, not a generic questionnaire.*

---

How Compounding Pharmacies Legally Operate

The other half of the legal picture is where your medication is actually prepared. This is where a lot of the online confusion comes from, and where the details genuinely matter.

Federal law, specifically Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a), allows state-licensed pharmacies to compound, meaning individually prepare, a medication for a specific, named patient based on a valid prescription. This is a long-standing, FDA-recognized legal pathway. It is not a loophole, and it predates the recent GLP-1 shortage entirely; it exists so patients can get medications customized to a documented clinical need, such as an allergy to an inactive ingredient in the commercial product, a dosage strength that is not commercially manufactured, or a different route of administration when there is a documented medical reason for it.

It is important to be precise about what currently justifies this pathway for semaglutide and tirzepatide specifically. During 2022 through 2024, both drugs were on the FDA's drug shortage list, which created a separate, temporary compounding allowance tied specifically to the shortage. That shortage-based allowance is no longer in effect. The FDA removed tirzepatide from the shortage list in late 2024 and removed semaglutide in February 2025, and enforcement discretion tied to those shortages ended shortly after. Compounding semaglutide or tirzepatide today because the drug was once in shortage is not a valid legal basis, and no legitimate provider should describe it that way.

What remains legally available is patient-specific compounding for a documented clinical reason under Section 503A's ordinary framework, filled at low volume for an individual patient with an identified, non-formulaic justification in the medical record. The FDA's April 2026 guidance on what counts as "essentially a copy" of a commercially available drug reinforces this: patient-specific compounding tied to a real clinical rationale remains permitted; mass-producing a near-identical formulation for any patient who asks does not.

In practical terms, this means a legitimate 503A pharmacy will be able to explain, specifically, why your prescription qualifies, not simply point to a shortage that ended over a year ago.

---

Red Flags of an Illegitimate Provider

Illegal or unlicensed sellers tend to share a recognizable pattern. Watch for:

• "No prescription needed" or "no doctor visit required." Any legitimate access to semaglutide or tirzepatide, brand or compounded, requires a valid prescription from a licensed provider. There is no legal way around this.
• No real clinical intake. If the entire process is a short checkbox form with no follow-up questions, no review of your medical history, and no way to ask a provider anything, that is not a legally adequate evaluation.
• Unclear or hidden pharmacy sourcing. A legitimate provider will tell you which licensed pharmacy is preparing your medication. If a seller will not name their pharmacy or cannot confirm state licensure, that is a serious warning sign.
• Marketing that claims FDA approval it doesn't have. Compounded semaglutide and tirzepatide are not FDA-approved. Any seller claiming otherwise, or claiming a compounded product is "the same as" the brand-name drug, is making a false and potentially illegal claim under FTC advertising rules.
• Prices dramatically below what licensed compounding actually costs. Extremely cheap pricing is often a sign that a product was sourced from an unregulated, non-pharmaceutical-grade ingredient supplier rather than an FDA-registered manufacturer.

The FDA has issued more than 55 warning letters to online sellers of compounded GLP-1 medications since late 2025, citing exactly these practices: compounding without documented medical necessity, unlicensed manufacturing, misleading marketing, and poor-quality ingredient sourcing.

*A legitimate telehealth provider can clearly explain the licensing and regulatory basis behind every prescription it issues.*

---

How to Verify a Provider Is Legitimate

Before starting treatment anywhere, a few checks take just a few minutes and tell you a lot:

Check for LegitScript certification. LegitScript is an independent third party that certifies healthcare merchants against standards covering licensing, transparency, and advertising practices. A currently certified platform has been independently vetted against those standards. Prescriva holds an active LegitScript Healthcare Merchant Certification.

Verify the pharmacy's state license. Every state pharmacy board maintains a public license lookup. A legitimate provider will tell you which pharmacy fills your prescription, and you can confirm that license yourself in under a minute.

Confirm the prescribing provider is licensed in your state. You are entitled to know who is reviewing your case and where they are licensed. A legitimate telehealth platform will tell you this without hesitation.

Ask what makes your prescription patient-specific. If you are being offered a compounded formulation, ask your provider to explain, specifically, the clinical reason for it. A clear, documented answer is a good sign. A vague or evasive one is not.

Read the actual disclaimers. Legitimate telehealth companies are direct about what is and is not FDA-approved, and they do not describe a management services organization as if it were the medical practice itself.

---

Frequently Asked Questions

Is it legal to get semaglutide through telehealth? Yes. A licensed physician can legally evaluate you through telehealth and prescribe semaglutide, whether that is an FDA-approved brand like Wegovy or a compounded version prepared by a licensed 503A pharmacy for a documented clinical reason, in every U.S. state.

Is compounded semaglutide or tirzepatide still legal in 2026? Yes, within a narrower framework than during the 2022 to 2024 shortage period. Patient-specific compounding by a state-licensed 503A pharmacy remains a legally recognized pathway under 21 U.S.C. § 353a when there is a documented clinical reason for it. Compounding based only on the fact that these drugs were once in shortage is no longer a valid legal basis, since both drugs have since been removed from the FDA's shortage list.

Do I need a video call to get a legal prescription? It depends on your state. Many states permit a thorough asynchronous (written) intake reviewed directly by a licensed provider, while some require a live visit, particularly for an initial prescription. What matters legally in every state is that a real clinical evaluation occurs, not the specific format it takes.

Why do some online sellers not require a prescription at all? Because they are operating illegally. There is no legal pathway to obtain semaglutide or tirzepatide, brand-name or compounded, without a valid prescription from a licensed provider. Sites offering it without one are not a legal gray area; they are outside the law.

How can I tell if my provider's pharmacy is licensed? Ask directly which pharmacy fills your prescription, then look up that pharmacy on your state's board of pharmacy license lookup tool. A legitimate 503A pharmacy will have an active, verifiable state license.

---

What Prescriva Does

Prescriva is a telehealth platform and management services organization. We do not manufacture medications, dispense prescriptions, or make clinical decisions. Every patient is evaluated by an independently licensed healthcare provider in Prescriva's affiliated network, licensed in the patient's state, before any prescription is issued. Medications are dispensed by state-licensed pharmacies, and compounded formulations are prepared by 503A pharmacies based on documented, patient-specific clinical need, not a shortage designation.

Prescriva holds an active LegitScript Healthcare Merchant Certification, reflecting independent verification of our licensing, transparency, and advertising practices.

*Compounded semaglutide and tirzepatide are not FDA-approved. They are not the same as, equivalent to, or interchangeable with FDA-approved products such as Wegovy, Ozempic, Zepbound, or Mounjaro. Individual results vary. Consult your healthcare provider before starting any new medication.*

[Check your eligibility](/assessment) for a licensed, provider-guided evaluation with Prescriva.

---

The Bottom Line

• Telehealth prescribing of semaglutide and tirzepatide is legal nationwide when a physician licensed in your state conducts a real clinical evaluation and issues a valid, individual prescription.
• Compounding remains a legal pathway, but it now depends on a documented, patient-specific clinical reason under 21 U.S.C. § 353a, not on either drug's shortage history, since both have been off the FDA shortage list since late 2024 (tirzepatide) and February 2025 (semaglutide).
• The clearest signs of an illegitimate seller are no prescription requirement, no real clinical intake, hidden pharmacy sourcing, and false FDA-approval claims.
• Verifying a provider takes only a few minutes: check for LegitScript certification, confirm state pharmacy licensure, and ask your provider to explain the clinical basis for your specific prescription.

If you are ever unsure about a provider, the safest step is to ask direct questions about licensing and sourcing before starting treatment. A legitimate provider will always have clear answers.

---

*This article is not medical advice. Consult a licensed healthcare provider with questions about your specific treatment plan.*

---

Sources used in this article:

• 21 U.S.C. § 353a (Federal Food, Drug, and Cosmetic Act, Section 503A compounding provisions)
• [FDA: Human Drug Compounding](https://www.fda.gov/drugs/human-drug-compounding)
• [FDA Drug Shortages Database](https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm)
• [FDA Drug Safety and Availability: Compounded Drug Products](https://www.fda.gov/drugs/drug-safety-and-availability/compounded-drug-products-atc)
• [LegitScript Healthcare Certification Standards](https://www.legitscript.com/certification/healthcare-certification/standards/)

---

See Also

• [How to Evaluate a Compounded GLP-1 Provider: What to Look for in 2026](/resources/how-to-evaluate-compounded-glp1-provider-503a-pharmacy)
• [Is Compounded Semaglutide Safe?](/resources/is-compounded-semaglutide-safe)
• [Compounded Semaglutide Regulations 2026: What Patients Need to Know](/resources/compounded-semaglutide-regulations-2026)